semaglutide and heart disease in Cardiometabolic Diseases: SELECTing the Target Population FDA Clears Semaglutide For Cardiac

A higher proportion of Japanese subjects reported gastrointestinal adverse events than Caucasian subjects: 62.5%, 37.5%, and 16.7% of Japanese subjects receiving semaglutide 0.5, 1.0 mg and placebo, respectively, versus 25.0%, 25.0% and 0.0% of Caucasian subjects, respectively (Supplementary Table S3)

they may also have direct effects in the brain (animal studies show neuroprotection and reduced amyloid/tau pathology)

Results from her current study are expected in the fall

Firstly, tirzepatide has lipid-lowering effects, reducing total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglyceride levels, while increasing high-density lipoprotein cholesterol (HDL-C), thereby mitigating lipid deposition in arterial walls [23]

Monoamine neurotransmitter disordersclinical advances and future perspectives

Centers for Medicare & Medicaid Services (2026) Medicaid coverage of and spending on GLP-1s, KFF (2026) Tirzepatide as compared with semaglutide for the treatment of obesity, The New England Journal of Medicine (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice